suPAR as a marker of diabetic nephropathy in patients with type 2 diabetes

被引：0
作者：
Wang, Tao [1 ,2 ]
Zhang, Qingjuan [2 ]
Liu, Meng [2 ]
Lu, He [1 ]
Lu, Huan [1 ]
Zhu, Jiang [2 ]
Yuan, Zijing [2 ]
Li, Jianbo [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Nephrol, Gushan Rd 168, Nanjing 211100, Jiangsu, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2019年 / 12卷 / 04期
关键词：
Soluble urokinase plasminogen activator receptor (suPAR); type 2 diabetic nephropathy; biomarker; GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; SERUM CREATININE; RISK-FACTORS; MICROALBUMINURIA; EXPRESSION;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Objective: The aim of this study was to investigate the association of serum levels of soluble urokinase plasminogen activator receptor (suPAR) with early stages of diabetic nephropathy in patients with type 2 diabetes. Methods: A total of 106 patients with type 2 diabetes and 13 healthy controls were recruited, from January 2016 to December 2017. Serum suPAR, estimated glomerular filtration rates (eGFR), and urine albumin-creatinine ratios (UACR) were determined in all participants. Other clinical risk factors for diabetic nephropathy were collected. Results: Serum levels of suPAR in patients with type 2 diabetes were significantly higher than in healthy controls (620.2 +/- 456.4 pg/mL vs. 390.3 +/- 60.4 pg/mL, P < 0.05). UACR and eGFR were significantly increased from the lowest to highest quartile of suPAR (p for trend < 0.05). After adjusting for other clinical risk factors via multivariate regression analysis, serum levels of suPAR proved to be an independent contributor to eGFR (beta = -3.614, t = -4.281, P < 0.001). Conclusion: Serum levels of suPAR were independently associated with eGFR, suggesting the role of a potential biomarker predicting early stages of diabetic nephropathy.
引用
收藏
页码：4218 / 4225
页数：8
相关论文
共 28 条
[1]   Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review [J].
Backes, Yara ;
van der Sluijs, Koenraad F. ;
Mackie, David P. ;
Tacke, Frank ;
Koch, Alexander ;
Tenhunen, Jyrki J. ;
Schultz, Marcus J. .
INTENSIVE CARE MEDICINE, 2012, 38 (09) :1418-1428
[2]  
Close CF, 1999, DIABETIC MED, V16, P918
[3]   Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer [J].
de Bock, CE ;
Wang, Y .
MEDICINAL RESEARCH REVIEWS, 2004, 24 (01) :13-39
[4]  
De Witte H, 1998, INT J CANCER, V77, P236, DOI 10.1002/(SICI)1097-0215(19980717)77:2<236::AID-IJC12>3.0.CO
[5]  
2-9
[6]   Histopathology of diabetic nephropathy [J].
Fioretto, Paola ;
Mauer, Michael .
SEMINARS IN NEPHROLOGY, 2007, 27 (02) :195-207
[7]   Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels [J].
Gustafsson, Anna ;
Ajeti, Vjosa ;
Ljunggren, Lennart .
BIOMARKER INSIGHTS, 2011, 6 :119-125
[8]  
Guthoff M, 2017, SCI REP, V7
[9]   Soluble Urokinase Receptor and Chronic Kidney Disease [J].
Hayek, Salim S. ;
Sever, Sanja ;
Ko, Yi-An ;
Trachtman, Howard ;
Awad, Mosaab ;
Wadhwani, Shikha ;
Altintas, Mehmet M. ;
Wei, Changli ;
Hotton, Anna L. ;
French, Audrey L. ;
Sperling, Laurence S. ;
Lerakis, Stamatios ;
Quyyumi, Arshed A. ;
Reiser, Jochen .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) :1916-1925
[10]   The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status [J].
Heraclides, A. ;
Jensen, T. M. ;
Rasmussen, S. S. ;
Eugen-Olsen, J. ;
Haugaard, S. B. ;
Borch-Johnsen, K. ;
Sandbaek, A. ;
Lauritzen, T. ;
Witte, D. R. .
DIABETOLOGIA, 2013, 56 (07) :1542-1546
123